Genmab — Maj 2014
-
US ser noget shaky ud - og pcyc får kampstryg. På den baggrund er GENs performance i dag absolut godkendt!
-
Ibrutinib salg på ca. 110 mio. $ i Q1: http://finance.yahoo.com/news/pharmacyclics-reports-first-quarter-2014-120000173.html
-
man skal tage PCYC tal og *2 det er da noget bedre end de 13 mio. CHF rottegiften fra roche kunne prale af
-
"To date, in addition to the upfront payment of $150 million, the Company has received milestone payments of $445 million under the Agreement. " det er på ca. 3 år de har fået det beløb fra Jannsen. Nogen der glæder sig til dara milestones de næste par år
-
arh okay. Det samlede salg var 56 mio. $ som så skal deles 50/50 mellem PCYC og J&H
-
RRMS studiet giver da en pæn omtale i diverse medier: http://www.medpagetoday.com/MeetingCoverage/AAN/45580
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind